Tyr324
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr324  -  PGK1 (human)

Site Information
GPESSkkyAEAVTRA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 5233200
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 1 ) , immunoassay ( 1 ) , mass spectrometry ( 2 , 3 , 4 , 5 , 6 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
brain cancer ( 1 ) , astrocytoma ( 1 ) , glioblastoma ( 1 ) , glioblastoma multiforme ( 1 ) , glioma ( 1 ) , lung cancer ( 2 , 3 , 4 , 5 , 6 ) , non-small cell lung cancer ( 2 , 4 , 5 , 6 ) , non-small cell lung adenocarcinoma ( 2 , 3 , 4 , 5 , 6 ) , non-small cell large cell lung carcinoma ( 2 , 4 ) , non-small cell squamous cell lung carcinoma ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
PGK1 (human) ( 1 )
Kinases, in vitro:
PGK1 (human) ( 1 )
Putative upstream phosphatases:
PTEN (human) ( 1 )
Treatments:
ATP ( 1 ) , doxycycline ( 1 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on PGK1:
enzymatic activity, induced ( 1 ) , protein conformation ( 1 )
Effects of modification on biological processes:
apoptosis, induced ( 1 ) , carcinogenesis, induced ( 1 ) , cell growth, induced ( 1 )

References 

1

Qian X, et al. (2019) PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1. Mol Cell
31492635   Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info